Actavis PT Raised to $230.00 at JPMorgan Chase & Co. (ACT)
Analysts at JPMorgan Chase & Co. lifted their price target on shares of Actavis (NYSE:ACT) from $215.00 to $230.00 in a research report issued to clients and investors on Monday, AnalystRatingsNetwork.com reports. JPMorgan Chase & Co.’s price target suggests a potential upside of 26.33% from the company’s current price.
Actavis (NYSE:ACT) traded down 3.66% on Monday, hitting $182.07. The stock had a trading volume of 2,203,931 shares. Actavis has a one year low of $82.02 and a one year high of $191.17. The stock has a 50-day moving average of $174.1 and a 200-day moving average of $151.4. The company’s market cap is $31.680 billion.
A number of other firms have also recently commented on ACT. Analysts at Piper Jaffray raised their price target on shares of Actavis from $175.00 to $203.00 in a research note to investors on Tuesday, January 28th. They now have an “overweight” rating on the stock. Separately, analysts at Argus raised their price target on shares of Actavis from $180.00 to $198.00 in a research note to investors on Friday, January 17th. They now have a “buy” rating on the stock. Finally, analysts at Cowen and Company upgraded shares of Actavis from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, January 10th. They now have a $215.00 price target on the stock, up previously from $130.00. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $175.16.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.